With marijuana rescheduling still left unfulfilled months after President Donald Trump ordered the process to be completed, there are no plans to update federal workplace drug policy around cannabis, according to a new filing from the U.S. Department of Health and Human Services (HHS).
In a noticed published in the Federal Register on Friday, HHS and the Substance Abuse and Mental Health Services Administration (SAMHSA) advised that they’ve “made no revisions to the current drug testing panels for both urine and oral fluid and current required nomenclature” for labs and medical review officer reports.
Because marijuana remains a Schedule I drug under the Controlled Substances Act (CSA), drug testing standards for the substance are not changing for federal workers, at least for now. “The current authorized drug testing panels and required report nomenclature remain in effect,” the notice says.
The relevant rule is meant to identify the “analytes and cutoffs for federal agency workplace drug testing specimens” and lay out “the nomenclature (i.e., analyte names and abbreviations) that must be used to report federal workplace drug test results.” Statute dictates that HHS must periodically provide updates on the rule, even if it’s not being revised as in this case.
Because the
Read full article on Marijuana Moment
